Johnson & Johnson to Discontinue Phase 2 Field Study Evaluating Investigational Antiviral for the Prevention of Dengue

Raritan, N.J. (October 4, 2024) – Johnson & Johnson announced today it is discontinuing the Phase 2 field study (NCT05201794) evaluating the efficacy of investigational antiviral candidate mosnodenvir for the prevention of dengue virus in adults aged 18-65 years. The decision to discontinue this study is part of a strategic reprioritization of the Company’s Communicable Diseases research and development (R&D) portfolio. No safety issues were identified.

Efficacy data from the Phase 2 field study will be available once the final data analyses, which are now underway, are complete. Study investigators have been notified of the discontinuation. All participants have completed the study per protocol and will be notified of the results once they are ready.

Mosnodenvir (formerly JNJ-1802) was shown to be safe and well tolerated in previous Phase 1 and Phase 2a clinical studies. Results from the Phase 2a human challenge study found that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo.

Johnson & Johnson will continue to support the fight against dengue by sharing study results with the medical community in the future.

Johnson & Johnson’s Commitment to Communicable Diseases
Communicable diseases are some of the world’s most entrenched health challenges, impacting the health and safety of billions of people around the world every year. Our Communicable Diseases program builds on our decades of work addressing tuberculosis, HIV, extraintestinal pathogenic E. coli (ExPEC) and neglected tropical diseases like leprosy to help improve lives and create hope for a healthier, safer world.

You can learn more about our efforts to address communicable diseases by visiting the Johnson & Johnson Innovative Medicine website.

About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/.

© Janssen-Cilag International NV. All rights reserved.